SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

Press Release:

10 Scientific Presentations on the SynCardia temporary Total Artificial Heart Will Be Given at The International Society for Heart & Lung Transplantation’s 36th Annual Meeting

The SynCardia temporary Total Artificial Heart powered by the Freedom® portable driver. The SynCardia temporary Total Artificial Heart powered by the Freedom® portable driver. TUCSON, Ariz. – Apr. 22, 2016 –  The 36th Annual Meeting of the ISHLT will be held at the Marriott Wardman Park Hotel in Washington D.C. April 27-30, 2016.

The SynCardia Total Artificial Heart is the only approved device in use that, like a heart transplant, eliminates the source of end-stage biventricular (both sides) heart failure.

Thursday, April 28, 6-7 p.m.
“Desensitization in Total Artificial Heart Patients”
J. Neyer, M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, R. Jocson, C. Runyan, D. Chang, J. Moriguchi, A. Trento, J.A. Kobashigawa, F. Arabia

Thursday, April 28, 6-7 p.m.
“Ethical Analysis of Withdrawing Total Artificial Heart Support”
E.S. DeMartino, S.E. Wordingham, D.P. Sulmasy, J.M. Stulak, B.A. Boilson, K.R. Fuechtmann, N. Singh, O.E. Pajaro, P.S. Mueller

Thursday, April 28, 6-7 p.m.
“Worldwide Use of SynCardia Total Artificial Heart in Pediatric Population: A 30-Year Experience”
A. Lorts, R. Rizwan, F. Zafar, J.L. Jefferies, J.S. Tweddell, F.A. Arabia, D.L. Morales

Thursday, April 28, 6:50-6:55 p.m.
“Competing Outcomes of Heart Transplantation in Adults Bridged with Total Artificial Heart (TAH): UNOS Registry Analysis”
E.C. DePasquale, A. Salimbangon, A. Chang, E. Howell, S. Lin, A. Nsair, M. Deng, A. Ardehali

Friday, April 29, 2:45-3 p.m.
“Biventricular Bridge to Transplant: Total Artificial Heart (TAH) vs. Thoratec Paracorporeal VADs (PVADs) Outcomes Post Heart Transplant (HT)”
E.C. DePasquale, A. Salimbangon, E. Howell, A. Chang, A. Nsair, A. Ardehali

Friday, April 29, 3:15-3:30 p.m.
“Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events in Intermacs”
F. Arabia, I. Gregoric, V. Kasirajan, J.D. Moriguchi, D.C. Naftel, S.L. Myers, J.K. Kirklin

Friday, April 29, 6-7 p.m.
“Successful Heart Transplantation in Patients with Total Artificial Heart Infections”
S. Taimur, T. Sullivan, M. Rana, G. Patel, K. Ashley, J. Roldan, B. Griffin, S. Pinney, A. Anyanwu, S. Huprikar

Friday, April 29, 6-7 p.m.
“Excessive Hemolysis in a Patient with JAK 2 Mutation After Total Artificial Heart Implantation Resolved by Changing from C2 Driver to Freedom Driver”
E.A. Helwig, J. Pisano, B. Soleimani, E. Stephenson, W. Pae, A. Ghodsizad, C. Brehm

Friday, April 29, 6:45-6:50 p.m.
“Left Ventricular, Biventricular and Total Artificial Heart Support are Associated with Similar Levels of Allosensitization in Bridge-to-Transplant Patients: An Analysis of the UNOS Database”
M. Yuzefpolskaya, P.N. Trinh, A.R. Garan, K. Takeda, H. Takayama, D.M. Mancini, Y. Naka, V.K. Topkara, K. Wong, F. Castagna, P.C. Colombo

Saturday, April 30, noon-12:15 p.m.
“The Worldwide Experience of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease”
D.L. Morales, R. Rizwan, F. Zafar, C. Villa, J.L. Jefferies, R. Bryant III, F.A. Arabia, A. Lorts

Please note that this information refers to third-party presentations of material related to the SynCardia Total Artificial Heart and the views expressed at ISHLT by any speaker or panelist who is not an employee of SynCardia do not necessarily reflect the views of SynCardia Systems, Inc.

###

About the SynCardia Systems, Inc.

SynCardia Systems, Inc. in Tucson, Arizona is a medical technology company focused on developing and manufacturing the SynCardia temporary Total Artificial Heart (TAH-t). The SynCardia TAH-t is an implantable system designed to assume the full function of a failed human heart in patients suffering from end-stage biventricular (both sides) heart failure.

The SynCardia TAH-t is the only total artificial heart that is commercially available in the United States, European Union and Canada for use as a bridge to donor heart transplantation.

More than 1,580 implants of the SynCardia Total Artificial Heart account for over 530 patient years of life on the device. Since January 2012 more than 600 SynCardia Hearts have been implanted.

The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart and received a successful donor heart transplant was nearly four years (1,373 days).

SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital and live at home and in their communities. The Freedom® portable driver has been used by more than 275 patients, accounting for over 180 patient years of support.

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas